Heidelberg, Germany; 13 November 2008 - mtm laboratories, a fully integrated cancer diagnostics company with proprietary products marketed globally, today announced that it will be presenting at BIO-Europe in Mannheim, Germany on 19 November 2008. The presentation by Bob Silverman, CEO of mtm laboratories, will include mtm’s biomarker-based diagnostic and screening products for the accurate diagnosis of cervical cancer, the largest existing screening market in oncology.
The biomarker that mtm uses in its screening and diagnostic products is the cyclin-dependent kinase inhibitor p16INK4a, the over-expression of which has been shown to be a highly specific marker of the onset of cervical cancer. It is crucial to a positive prognosis that cervical cancer is identified and treated as early as possible and p16INK4a as a biomarker makes such early accurate diagnoses possible.
BIO-Europe brings together international decision-makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities, workshop participation, and private, pre-scheduled one-to-one meetings. Investment and collaboration opportunities developed in prior BIO- Europe conferences have produced many highly successful business partnerships.
mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with the headquarter in Heidelberg, Germany and subsidiaries in the United States, France, Italy and Spain. Further information can be found at: www.mtmlabs.com.
